Tick-borne encephalitis virus (TBEV) encodes a conserved, immunogenic, non-structural protein NS1 that is glycosylated and secreted from infected cells in an oligomeric form. An adenovirus recombinant, RAd51, expressing high levels of TBEV NS 1 has previously been demonstrated to protect mice against a lethal challenge with TBEV. We show here that BALB/c mice infected with TBEV experienced a transient viraemia between days 3 to 5 post-inoculation that was detectable prior to the encephalitic phase of infection. Mice vaccinated with RAd51 were protected against both the viraemic and encephalitic infections associated with the TBEV challenge. Protection was demonstrated to be due to NS 1 synthesized de novo from RAd5 l in the vaccinated mice. Since TBEV NS1 is expressed on the cell surface, antibody-dependent complement-mediated cytolysis (CMC) of infected cells was considered as a possible mechanism of protection. Vaccination with the recombinant adenovirus proved to be effective in a mouse strain carrying a genetic deletion in the complement receptor C5. CMC is therefore not an essential component of the observed protective immune response.
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The family Flaviviridae contains a number of clinically important arboviruses which can be divided into mosquito-borne [e.g. yellow fever virus (YFV), dengue virus] and tick-borne (e.g. tick-borne encephalitis virus (TBEV) (De Madrid & Porterfield, 1974; Calisher et al., 1989) . The majority of tick-borne flaviviruses fall into a single serological group with TBEV itself being divided into the Central European and Far Eastern subtypes (Heinz & Kunz, 1981) . Like other flaviviruses, TBEV is an enveloped virus containing a positive-sense, ssRNA genome that is translated into a long polyprotein of over 3000 amino acids. The polyprotein is cleaved by proteolysis into at least three structural and seven nonstructural proteins. Although a number of successful flavivirus vaccines have been developed, concern exists over the possibility of inducing sub-neutralizing levels of antibody to virion surface proteins with the potential for antibody-dependent enhancement (ADE) of infection, a phenomenon associated particularly with dengue haemorrhagic fever and demonstrated for other flaviviruses in experimental models (Hawkes, 1964; Hawkes & Lafferty, 1967; Halstead, 1982; Kayser et al., 1985; Phillpotts et al., 1985; Gould et al., 1987;  t Present address: Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, U.K. $ Present address: Department of Medicine, University of Wales College of Medicine, Cardiff CF4 4XX, U.K. Gould & Buckley, 1989) . As a consequence of ADE, there is interest in developing a new generation of vaccines based on non-structural proteins. The secreted flavivirus non-virion protein glycoprotein NS1 was recognized as a potential vaccine candidate following demonstrations that inoculation of purified NS1 or monoclonal antibodies (MAbs) to NS1 could protect against virus challenge with YFV and dengue virus (Schlesinger et al., 1985 (Schlesinger et al., , 1986 (Schlesinger et al., , 1987 Gould et al., 1986) .
The recombinant adenovirus RAd51 is an adenovirus type 5 dl309 E1 deletion mutant that contains the TBEV strain Neudorfl NS1 gene cloned under the control of the powerful constitutive cytomegalovirus major immediate early promoter. RAd51 was propagated in a helper cell line expressing the E1 gene region (293 cells) and then used to infect non-permissive cells in vitro or to vaccinate mice. High-level expression of a secreted and appropriately processed dimeric recombinant NS1 was detected in human fibroblasts in cell culture and the recombinant was shown to provide protection to TBEV challenge when inoculated into BALB/c mice (Jacobs et al., 1992) . In both investigating the mechanism of protection elicited to TBEV and evaluating the potential of the adenovirus-based vector system in vaccine development, it was important to differentiate between an immune response to NS 1 antigen which could be present in the RAd51 inoculum and to NS1 synthesized de novo in the vaccinated mice.
293 cells infected with RAd51 were harvested by 0001-2354 © 1994 SGM centrifugation (1000 r.p.m, for 10 min in an MSE Mistral centrifuge), resuspended in PBS and extracted with an equal volume of the solvent Arklone-P (Basic Chemical Company). Half of the virus preparation was stored at -70 °C and the remainder purified by velocity centrifugation through CsC1 gradients (twice) as described by Precious & Russell (1985) . Following dialysis of the gradient-purified virus against PBS, both stocks of virus were diluted to 1 x l0 s p.f.u./ml in PBS. Aliquots of both stocks were irradiated with u.v. light at 1'5 mW/cm 2 for 0s, 60s (0.9mJ/mm2), 120s (1-SmJ/mm2), 5min (4.5 mJ/mm2), 10 rain (9"0 mJ/mm 2) and in each case 4.5 mJ/mm 2 was found to be the minimum exposure required to inactivate detectable plaque formation (< 107 plaque reduction) and NS1 expression in infected cells as assayed by immunofluorescence. Expression of NS1 was assayed 24 h post-infection of PS cells by immunofluorescence using the anti-NS1 MAb T12 (Stephenson et al., 1984) . BALB/c mice were immunized three times intraperitoneally (i.p.) at 0, 1 and 3 weeks with 100 gl of the adenovirus recombinant treated as indicated in Table 1 and 1 week following the final inoculum challenged subcutaneously with 10 LD.s o units of Neudorfl strain TBEV as described by Jacobs et al. (1992) . Control mice given PBS, and mice receiving u.v.-treated RAd51 (with or without CsC1 purification) did not survive challenge with TBEV. Mice vaccinated with non-irradiated virus exhibited a significant level of protection to the virus challenge both with (seven out of eight mice) and without (five out of eight mice) gradient purification. TBEV challenge produced no disease symptoms in the surviving RAd51-vaccinated mice. The presence of contaminating NS1 protein even in the non-gradient-purified RAd51 (u.v.-inactivated) preparation did not afford protection to lethal virus challenge (Tabel 1). In this experimental system, de novo expression of NS1 from RAd51 appears to be required to generate a protective immune response.
We were interested in investigating the pathogenesis of the TBEV-induced disease produced in both the vaccinated and non-vaccinated mice. In a simple time-course experiment mice were immunized with RAd51, RAd35 or PBS according to the prescribed schedule and challenged i.p. with TBEV Neudorfl strain. RAd35 was used as a control adenovirus recombinant expressing an unrelated gene product, fl-galactosidase (Wilkinson & Akrigg, 1992) . Mice from each group were sacrificed every day post-challenge, blood was taken by cardiac puncture and brain homogenate was prepared in PBS. Daily samples from the two control groups (RAd35, PBS) were pooled; samples from the RAd51-inoculated mice remained separate and identifiable. Brain extracts or sera were inoculated onto PS cells grown on glass coverslips, the cells were incubated for 7 days and the presence of replicating TBEV was detected by immunofluorescence using an anti-E MAb (Stephenson et al., 1984) .
In the control mice vaccinated with RAd35 or PBS a viraemia was detected between days 2 to 5 post-challenge; however TBEV was not detectable in the brain samples until day 5 where the infection persisted to the time of death (Table 2 a). By day 11, all control mice had either been harvested or died. With three exceptions, neither a viraemia nor encephalitic infection was detected in the RAd51-vaccinated mice challenged with TBEV (Table  2b ). The exceptions included a mouse taken on day 6 post-challenge in which both a viraemia and encephalitic infection were detected and two mice, one taken on day 11 and one on day 13, in which virus was detected in the brain only. Since vaccination with the recombinant adenovirus does not afford 100% protection the detection of TBEV in a proportion of the vaccinated mice was expected. The possibility that TBEV NS1 deletion mutants capable of evading the anti-NS1 immune surveillance were being selected by vaccination was considered. However, TBEV recovered from the serum * Experiments were performed concurrently. PS cells were infected with either sera or brain cell extract, incubated for 7 days and the presence of replicating TBEV detected by immunofluorescence.
t Results for (a) are from samples taken from two mice and pooled. -, No virus detected; +, virus detected. and brain samples of the RAd51-vaccinated mice were re-examined and shown in immunofluorescence assays to be recognized by the anti-NS1 MAbs T12, T33/1 and T33/3 (data not shown). TBEV challenge of unprotected mice produced a transient viraemia which preceded neuroinvasion. Vaccination with RAd51 protected the mice not only against death but also against both the viraemic and encephalitic phases of infection.
The mechanism by which vaccination with NS1 elicits protection has yet to be resolved not only for TBEV but also in other flavivirus systems. The observation that passive immunization with MAbs to YFV NS1 are protective implies that a humoral response can be sufficient (Schlesinger et al., 1985; Gould et al., 1986) . Since NS1 is expressed on the cell surface of flavivirusinfected cells, it has been postulated that antibodydependent complement-mediated cytotoxicity (CMC) could be a major factor eliminating virus-infected cells. To test the hypothesis that CMC was responsible for the RAd51-induced immunity, the protection experiments were repeated using an identical vaccination and challenge schedule in a congenic mouse strain deficient in C5. The LD~0 of TBEV as assayed in B10 D2 mice was identical to that measured in BALB/c mice so the TBEV challenge remained unchanged. A statistically significant level of protection was obtained in both normal B10 D2 (NSN) and B10 D2 mice deficient in the C5 receptor (OSN) immunized with RAd51 compared to control mice immunized with RAd35 (Table 3) . Fifty-six percent of OSN mice immunized with RAd51 survived TBEV challenge compared with 50 % of NSN mice, and using Fisher's exact test, significant protection was found to be obtained in both groups compared with mice immunized with RAd35 (P < 0-1). However, there was no significant difference in the level of protection in the OSN mice compared with that in the NSN mice. The terminal lyric pathway of the complement cascade therefore does not appear to be necessary for protection by RAd51 vaccination against challenge with TBEV. A correlation has also been made between the ability of individual YFV and dengue virus antibodies to protect mice against lethal virus challenge and to direct CMC when assayed in vitro (Schlesinger et al., 1985; Falgout et al., 1990) . However, Schlesinger et al. (1993) recently observed passive protection with a MAb to YFV NS 1 in mice in which C3 had been depleted by cobra venom factor. Determining the mechanism by which expression of this non-structural protein elicits a protective immune response is important if it is to be targeted in vaccine design but this has yet to be resolved. Both our results and recent experiments by Schlesinger et al. (1993) point to mechanisms other than CMC. A major advantage of the adenovirus vector system in vaccine development is its capacity to elicit both a humoral and a cell-mediated Short communication immune response, The protective response induced by the adenovirus recombinant may be attributable to a cell-mediated cytotoxic T cell response or to antibodydependent cell-mediated cytotoxicity.
